EGFR and pancreatic neoplasm: At the molecular level, pancreatic cancer exhibits high frequency of genetic alterations, including KRAS, TP53, CDKN2A and SMAD4 alterations, and aberrant activation of mitogenic signaling pathways as a consequence of overexpression of receptor tyrosine kinase (RTKs), such as epidermal growth factor (EGF) receptor (EGFR) and its ligands4.